Virtual Poster Session in NETs From Chicago - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in NETs From Chicago

Practical Application of Key Data Presented During the 2018 Oncology Annual Meeting

Not a member of My prIME? Join now for instant access.

View CME-certified presentations and downloadable slides covering the most up-to-date clinical trial data on neuroendocrine tumors (NETs) from the 2018 Oncology Annual Meeting in Chicago

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.5 AMA PRA Category 1 Credits

Release Date

Release Date

Jun 12, 2018

Expiration Date

Jun 12, 2019

Angela Lamarca, MD

Abstract #4094: Additional value of tumour growth rate (TGR) in patients (pts) diagnosed with well-differentiated neuroendocrine tumours (NETs) achieving RECIST-defined stable disease (SD): Subgroup analysis of the GREPONET study

Featured Expert: Angela Lamarca, MD

Ivan Borbath, MD, PhD

Abstract #4095: Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 European patients – The ENETS registry

Featured Expert: Ivan Borbath, MD, PhD

Jonathan Strosberg, MD

Abstract #4099: First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors

Featured Expert: Jonathan Strosberg, MD

  • Ivan Borbath, MD, PhDCliniques Universitaires Saint-Luc
    Woluwé-Saint Lambert, Belgium
  • Angela Lamarca, MDThe Christie NHS Foundation Trust
    Manchester, United Kingdom
  • Jonathan Strosberg, MDMoffitt Cancer Center
    Tampa, Florida, United States

This activity is specifically designed for physicians, nurses and other clinicians who are cancer specialists.

After successful completion of this educational activity, participants should be able to:

  • Discuss key NETs data from the conference
  • Apply key NETs data from the conference to clinical practice, as appropriate

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.; Ipsen; and Puma Biotechnology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Virtual Poster Virtual Poster Session in NETs From Chicago - prIME Oncology

prIME Oncology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the post-test are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Borbath has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lamarca has disclosed that she has received honoraria for promotional speaker’s bureaus and fees for speaking and teaching from Ipsen, Merck, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Strosberg has disclosed that he has received consulting fees from Novartis Oncology. He has also received honoraria for promotional speaker’s bureaus from Ipsen and Lexicon. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Angela Zimmermann, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.